TUSTIN, Calif., Jan. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. ( PPHM) today announced that Marvin R. Garovoy, MD, has joined the company as head of clinical science. Dr. Garovoy has extensive biotechnology industry experience in the design and conduct of clinical trials for innovative new drugs. At Peregrine, he will have primary responsibility for establishing and supervising an Investigator-Sponsored Trials (IST) program, as well as expanding scientific outreach and assisting with clinical trial design for the bavituximab and Cotara® programs. Dr. Garovoy brings extensive experience in the design and conduct of clinical trials and played a major role in the successful clinical development, regulatory approval and commercial launch of Raptiva®, a monoclonal antibody drug for the treatment of psoriasis jointly developed by XOMA and Genentech.
"As the bavituximab oncology program has advanced and begun yielding promising Phase II clinical data, a growing number of oncologists are expressing interest in conducting investigator-sponsored trials with bavituximab," said Steven W. King, president and CEO of Peregrine. "These ISTs can be a very important part of our overall clinical development program, potentially providing invaluable information that might not otherwise be obtained from our company-initiated trials. We are delighted that Dr. Garovoy is joining our clinical and regulatory team with primary responsibility for establishing this program. He has extensive experience in the design and conduct of clinical trials for novel biologic drug candidates and we expect that his efforts will contribute significantly to the success of this initiative."
Most recently, Dr. Garovoy has been chief medical officer at Arriva Pharmaceuticals, joining from Hyperion Therapeutics where he was senior vice president of clinical development. For most of the previous decade, Dr. Garovoy he
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved